Nagi Bioscience raises CHF 1.8 Million to accelerate its mission of setting a new standard for testing safety and efficacy of drugs and chemicals LAUSANNE, Switzerland – December 20, 2019 – Nagi Bioscience SA, a Swiss life-science-tech company developing a revolutionary technology for the in vitro testing of drugs and chemicals, announced today the closingRead more about Nagi Bioscience is proud to announce the closing of a CHF 1.8M Seed financing round[…]
Today, our CEO Matteo Cornaglia was on stage for pitching the company at the LaForge Startup Demo Day on EPFL campus. Good vibes and interesting connections with the attendees. Thank you La Forge for this opportunity to tell more about Nagi!
We are glad to announce that our application was accepted by the Novartis Foundation for Medical-Biological Research. This research project will be coordinated in collaboration with the Laboratory of Microsystems at EPFL headed by the Prof. Martin Gijs. We are looking forward to start this exciting project!
Nagi Bioscience wins the final phase of Venture Kick (130’000 CHF). The Venture Kick program has been an excellent support in terms of network, visibility and advices received from the coach and jury. Thank you Venture Kick for this truly significant support! We are very proud of this important achievement for our young. Let’s keep moving forward!Read more about Nagi Bioscience won Venture Kick final![…]
Nagi Bioscience is among the 20 finalists of the competition “Inventer Demain” organized by the RTS, France 3TV and Bilan magazine. Ten Swiss start-ups and ten other French companies are competing this year. This international competition aims to support entrepreneurs and startups in both countries, by shining the spotlight on ideas, pathways, discoveries and applications that couldRead more about Our startup is finalist of the competition “Inventer Demain”[…]
We are proud to be the winner (CHF 10’000 cash prize) of the startup competition organized by Philip Morris Equity Partner! This competition, organized in the framework of MassChallenge Switzerland, aimed to support innovative business which could have an impact on PMI’s value chain and its smoke free future vision. You can read the article publishedRead more about Nagi Bioscience won the Philip Morris Award Startup Competition![…]
According to the french web media Wydden, Nagi Bioscience is one of the 10 startups to follow in the BeautyTech industry! You can read the article published online by Wydden here. Good reading!
Nagi Bioscience passed stage 2 of Venture Kick! Let’s continue on our way: stage 3, here we come!
Nagi Bioscience is featured today in the online version of French Economic TV channel BFMTV. This article (in French) introduces the technology developed by our startup and its application for avoiding testing on animals for cosmetic, chemical industries and pharmas. You can read the article online here. Good reading!
Nagi Bioscience is featured today in the Economic Swiss newspaper Bilan. This article (in French) presents our startup and its device that avoids testing on animals for cosmetic, chemical industries and pharmas. You can read the article online here. Good reading!
We are glad to announce that Nagi is among the 66 high-impact startups that will join the final stage of the MassChallenge acceleration program. Our startup will benefit from world-class mentorship, programming, and resources during for improving our business case. The accelerator program will start in June and culminate on October 30th at the MassChallenge SwitzerlandRead more about Nagi Bioscience is part of the 2018 MassChallenge Accelerator Program[…]
Matteo and Laurent appeared respectively in two radio show broadcasted on the Swiss Radio RTS. They discuss the today’s problematic of animal testing and how the technology developed by Nagi Bioscience can bring an innovative solution to solve this issue. You can listen the live interview of Matteo and Laurent here and here (in French).
Our CSO Laurent Mouchiroud received the prestigious PERL (Prix Entreprendre Région Lausanne) Biotech Award 2018 during a ceremony held at the Theatre de Beaulieu in Lausanne. Each year, the PERL jury, made up of academic, economic and media representatives, is responsible for selecting and nominate the laureates. These laureates will benefit, before and after the prize-givingRead more about Nagi Bioscience won the PERL Biotech Award 2018[…]
An interview with Matteo Cornaglia, our CEO, was published on te front page of the EPFL website, providing some insight about the how and why of the technology developed by Nagi Bioscience. You can see the video entitled “Tech-Transfer:worms in high-tech housing replace laboratory mice” here.
Every year, 10 Swiss-based entrepreneurs with international high potential are selected by venturelab for the Swiss National Startup Team. The members of this team, the venture leaders, win a week entrepreneurial and business development training based in the Boston, US. In the context of the program, he is going to pitch at the Startup ChampionsRead more about Matteo was selected for Venture Leaders Life Sciences 2018[…]
Great news: Nagi Bioscience passed stage 1 of Venture Kick! On the way for stage 2 now! Venture Kick was launched in 2007 with the vision to double the number of spin-offs at Swiss universities, to accelerate the time-to-market and to raise the attractiveness of these young companies to professional investors and industry partners. Selected members fromRead more about Nagi Bioscience passed Venture Kick Stage I[…]
We are glad and very proud to be among the TOP50 start-up in which to invest in 2018 selected by the prestigious swiss economic newspaper Bilan. Every year, the magazine Bilan selects 50 of the most promising StartUps in Switzerland. A jury made up of innovation professionals selects Swiss nuggets, in fields as varied as fintech, biotech,Read more about Nagi Bioscience listed in Bilan’s top 50 Swiss start-up companies![…]
Nagi Bioscience is featured today in the Swiss newspaper Le Temps. This article (in French) discusses the current problematic of animal testing in the scientific research and highlight the solution developed by Nagi Bioscience. You can read the article online here or on the today’s paper version of the journal in the science section. Good reading!
From tomorrow morning till Friday evening, Nagi Bioscience will attend the Hello Tomorrow Summit in Paris as one of the World’s TOP500 Deep-Tech Startups. We are glad to be one of the startups selected for a showcase of our technology during this event. Come to visit us at booth #14 on Friday morning and seeRead more about Nagi Bioscience at the Hello Tomorrow Summit in Paris[…]
We are delighted to announce that our team will pitch the technology developed by Nagi Bioscience during the ILMAC Lausanne exhibition on Thursday, the 5th of October. The first-ever edition of ILMAC LAUSANNE is taking place on October 4 and 5, as the unique exhibition platform for the chemistry and life science community in the French-speaking partRead more about Our technology will be presented at ILMAC Lausanne 2017[…]
From September 10th to 13th, Nagi Bioscience attended the 53rd Congress of the European Societies of Toxicology (EuroTox) in Bratislava. Our team presented for the first time a poster with the latest results obtained in collaboration with Debiopharm SA.
We are delighted to announce that Nagi Bioscience has been chosen by Hello Tomorrow as one of the world’s TOP 500 deep-tech startups! Hello Tomorrow is a global not-for-profit organization created by deep tech entrepreneurs, with a mission to empower and connect the most promising deep-tech entreprises across the globe to accelerate the transfer of breakthrough technologies into real worldRead more about We made it to the TOP 500 in the Hello Tomorrow Global Challenge![…]
We are happy to announce the release of a new publication in collaboration with the Laboratory of Prof. Robin Gasser from the University of Melbourne. The article issued today in the FASEB Journal shows that deguelin, a plant-derived rotenoid, selectively and potently inhibits motility and development of nematodes, which supports its potential as a lead candidate for drugRead more about A collaborative study between the University of Melbourne (Prof. Gasser’s Lab) and the Nagi Bioscience team was published today[…]
In 2015, the project developed by Nagi Bioscience was the first recipient of the SGV 25th Fund. This fund was created by the SGV board to financially support projects related to the goals of the SGV, that are promotion of the Laboratory Animal Science and the Animal Welfare, and ethical considerations in animal experimentation. Read moreRead more about The platform developed by Nagi Bioscience is featured on the website of the Swiss Laboratory Animal Association (SGV)[…]
Gebert Rüf Stiftung fosters innovations for the benefit of Swiss economy and society, by supporting application-oriented and impact-oriented scientific projects at Swiss universities. The “Nematrix Project”, by Nagi Bioscience, became part of the GRS-supported project portfolio in November 2016.
The EPFL website and the Swiss French Radio (RTS) have covered the publication of our last scientific paper. The article was published in Molecular Neurodegeneration and shows data about the in vivo analysis of the long-term dynamics of protein aggregation in C. elegans at unprecedented resolution.
Our Business Idea (formerly known as Nematrix) was selected by the Jury Committee of >>venture>> 2015,out of a total of 107 submissions, as a TOP 10 winner of the business idea competition! The award ceremony took place at ETH Zurich in June 2015.